Integrated clinical, biochemical, cardiac imaging, and transcriptional changes under MEK inhibition in complicated Noonan syndrome
- 7 November 2026
- journal article
- research article
- Published by Springer Nature in European Journal of Human Genetics
- p. 1-9
Abstract
Hypertrophic cardiomyopathy (HCM) is a major contributor to morbidity and mortality in Noonan syndrome (NS), with a high risk of heart failure and arrhythmias. Lymphatic dysplasia represents another clinically significant manifestation often associated with significant morbidity. Emerging evidence suggests that MEK inhibitors may target these severe complications. Seven pediatric patients with molecularly confirmed NS and severe, treatment-refractory HCM and/or lymphatic effusions received oral trametinib treatment under compassionate use. Clinical, biochemical, and echocardiographic parameters were longitudinally assessed to evaluate efficacy and safety. Transcriptomic analysis of RAS/MAPK pathway-related gene expression was performed in a subset of patients at baseline, one week after treatment initiation, and during prolonged therapy. Trametinib treatment was maintained at doses ranging from 0.0075 to 0.033 mg/kg/day for 3–45 months. All patients showed a rapid decrease in NT-proBNP levels, followed by significant reductions in interventricular septal thickness and, when present, left ventricular outflow tract obstruction. In patients with lymphatic dysplasia, trametinib was associated with sustained reduction of pleural effusions and improved respiratory status. Treatment discontinuation led to progressive clinical and biochemical worsening, with improvement after reintroduction, when performed. Transcriptomic analysis demonstrated early modulation of RAS/MAPK pathway signatures in most patients. Adverse events were mild (grade 1), predominantly dermatological, and manageable with dose adjustments. These findings provide additional clinical and molecular evidence supporting trametinib treatment as a targeted therapeutic strategy for cardiac and lymphatic manifestations in NS. Prospective studies are needed to define long-term safety, optimal dosing, and treatment duration of MEK inhibition in NS and other RASopathies.Keywords
This publication has 42 references indexed in Scilit:
- RVOT Stenting and Trametinib in an Infant With Noonan Syndrome, Pulmonary Stenosis, and Hypertrophic CardiomyopathyJACC: Case Reports, 2025
- Impact of MEK Inhibition on Childhood RASopathy-Associated Hypertrophic CardiomyopathyJACC: Basic To Translational Science, 2024
- Trametinib Alters Contractility of Paediatric Noonan Syndrome-Associated Hypertrophic Myocardial Tissue SlicesESC Heart Failure, 2024
- The heart in RASopathiesAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2022
- The molecular genetics of RASopathies: An update on novel disease genes and new disordersAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2022
- Successful treatment with MEK‐inhibitor in a patient with NRAS‐related cutaneous skeletal hypophosphatemia syndromeGenes, Chromosomes and Cancer, 2022
- Clinical Presentation and Natural History of Hypertrophic Cardiomyopathy in RASopathiesHeart Failure Clinics, 2018
- Transcriptional hallmarks of noonan syndrome and noonan‐like syndrome with loose anagen hairHuman Mutation, 2012
- Regression Equations for Calculation of Z Scores of Cardiac Structures in a Large Cohort of Healthy Infants, Children, and Adolescents: An Echocardiographic StudyJournal of the American Society of Echocardiography, 2008
- PTPN11 gene mutations: linking the Gln510Glu mutation to the “LEOPARD syndrome phenotype”European Journal of Pediatrics, 2006